Finch Therapeutics Group Company Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn’s disease; and other microbiome product candidates.
The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota.
Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Matthew Blischak |
Contact Details
Address: 75 State Street Boston, Delaware 02109 United States | |
| Phone | 617 229 6499 |
| Website | finchtherapeutics.com |
Stock Details
| Ticker Symbol | FNCH |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US31773D1019 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Matthew P. Blischak J.D. | President, Secretary and Chief Executive Officer |
| Lance Thibault CPA | Chief Financial Officer |
| James S. Sigler MBA | Executive Vice President of CMC |